COVID-19: Gastrointestinal and hepatic manifestations and implications for clinical trials

May 31, 2020

Recent experience has indicated that the COVID-19 virus often presents as digestive discomfort, including abdominal pain, nausea and vomiting. For ongoing clinical trials, there is a danger of incorrectly reporting these symptoms. In this article, Parexel expert Michelle Pietzak, MD reviews current findings and offers practical recommendations for sponsors.

Previous Flipbook
EMA Guidance: Management of Clinical Trials - What it means for Patients?
EMA Guidance: Management of Clinical Trials - What it means for Patients?

A lay summary for patients participating in clinical trials

Next Flipbook
COVID-19 risks for pediatric patients and implications for clinical trials
COVID-19 risks for pediatric patients and implications for clinical trials

In this article, experts from the Parexel Pediatric Collaborative Group review current findings and conside...